Company / Shareholders' Equity
NovoCure Ltd Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$340.5M
FY2025
5-year range
$217.8M / $476.5M
FY2021-FY2025
Trend
-5.5%
vs FY2024
Sector context
#123 of 161
Health Care
What the data says
NovoCure Ltd's shareholders' equity of $340M is lower than 76% of companies in the Health Care sector (FY2025). Shareholders' Equity has declined for 3 consecutive years, from $477M in FY2022 to $340M in FY2025.
Based on SEC 10-K filings.
$340M in FY2025 with a 5-year CAGR of +24.8%.
Declined from $362M to $340M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -10.6%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 161This company $340.5M Sector average $5.1B
▼
-93.3% below sector average
Key checks
Key Insights
- NovoCure Ltd's shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 5.5% year-over-year.
- Ranks #123 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $340.5M | -5.5% |
| FY2024 | $360.2M | -0.6% |
| FY2023 | $362.5M | -23.9% |
| FY2022 | $476.5M | +118.8% |
| FY2021 | $217.8M | +94.0% |
| FY2020 | $112.3M | -1.1% |
| FY2019 | $113.6M | -20.2% |
| FY2018 | $142.3M | -43.2% |
| FY2017 | $250.8M | +156.3% |
| FY2016 | $97.9M | -43.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026